SEC
RARE icon

Seven Eight Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Seven Eight Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,478
Closed -$1.97M – 497
2024
Q3 		$1.97M Buy
35,478
+23,718
+202% +$1.21M 0.18% 186
2024
Q2 		$483K Sell
11,760
-35,796
-75% -$1.53M 0.05% 525
2024
Q1 		$2.22M Buy
47,556
+1,650
+4% +$77.8K 0.23% 128
2023
Q4 		$2.2M Buy
45,906
+26,831
+141% +$1.04M 0.25% 108
2023
Q3 		$680K Buy
19,075
+5,271
+38% +$209K 0.08% 330
2023
Q2 		$637K Buy
+13,804
New +$640K 0.11% 260
2022
Q4 		– Sell
-12,852
Closed -$532K – 590
2022
Q3 		$532K Buy
+12,852
New +$660K 0.11% 263
2022
Q2 		– Sell
-3,489
Closed -$253K – 580
2022
Q1 		$253K Buy
+3,489
New +$243K 0.03% 449
2021
Q3 		– Sell
-8,651
Closed -$825K – 698
2021
Q2 		$825K Buy
+8,651
New +$901K 0.12% 307
2020
Q1 		– Sell
-14,748
Closed -$630K – 658
2019
Q4 		$630K Sell
14,748
-26,800
-65% -$1.11M 0.03% 510
2019
Q3 		$1.78M Buy
+41,548
New +$2.26M 0.09% 321
2016
Q1 		– Sell
-300
Closed -$34K – 662
2015
Q4 		$34K Buy
+300
New +$30K 0.02% 462
2014
Q4 		– Sell
-100
Closed -$5.66K – 617
2014
Q3 		$5.66K Buy
+100
New +$5.03K ﹤0.01% 480

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Seven Eight Capital's RARE Position: Q4 2024 in Review

Seven Eight Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 35,478 shares — an estimated $1.97M sold.

Seven Eight Capital first reported a position in RARE in Q3 2014 and held it in 13 quarters. The position peaked at $2.22M in Q1 2024. 312 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

  • Seven Eight Capital reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 35,478 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $1.97M.
  • Seven Eight Capital first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 13 quarters.
  • Seven Eight Capital's Ultragenyx Pharmaceutical position peaked at $2.22M in Q1 2024.
  • 312 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.